Format

Send to

Choose Destination
J Ginseng Res. 2018 Oct;42(4):401-411. doi: 10.1016/j.jgr.2017.12.008. Epub 2018 Jan 12.

Panax ginseng as an adjuvant treatment for Alzheimer's disease.

Author information

1
Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea.
2
Department of Convergence Medicine, University of Ulsan College of Medicine and Institute of Life Science, Asan Medical Center, Seoul, Republic of Korea.
3
Department of Convergence Medical Science, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
4
Neuropsychopharmacology and toxicology program, College of Pharmacy, Kangwon National University, Chunchon, Republic of Korea.
5
Center for Neuroscience, Korea Institute of Science and Technology, Seoul, Republic of Korea.
6
Department of Neurology, Neuroscience Research Center, Seoul National University Hospital, Seoul, Republic of Korea.

Abstract

Longevity in medicine can be defined as a long life without mental or physical deficits. This can be prevented by Alzheimer's disease (AD). Current conventional AD treatments only alleviate the symptoms without reversing AD progression. Recent studies demonstrated that Panax ginseng extract improves AD symptoms in patients with AD, and the two main components of ginseng might contribute to AD amelioration. Ginsenosides show various AD-related neuroprotective effects. Gintonin is a newly identified ginseng constituent that contains lysophosphatidic acids and attenuates AD-related brain neuropathies. Ginsenosides decrease amyloid β-protein (Aβ) formation by inhibiting β- and γ-secretase activity or by activating the nonamyloidogenic pathway, inhibit acetylcholinesterase activity and Aβ-induced neurotoxicity, and decrease Aβ-induced production of reactive oxygen species and neuroinflammatory reactions. Oral administration of ginsenosides increases the expression levels of enzymes involved in acetylcholine synthesis in the brain and alleviates Aβ-induced cholinergic deficits in AD models. Similarly, gintonin inhibits Aβ-induced neurotoxicity and activates the nonamyloidogenic pathway to reduce Aβ formation and to increase acetylcholine and choline acetyltransferase expression in the brain through lysophosphatidic acid receptors. Oral administration of gintonin attenuates brain amyloid plaque deposits, boosting hippocampal cholinergic systems and neurogenesis, thereby ameliorating learning and memory impairments. It also improves cognitive functions in patients with AD. Ginsenosides and gintonin attenuate AD-related neuropathology through multiple routes. This review focuses research demonstrating that ginseng constituents could be a candidate as an adjuvant for AD treatment. However, clinical investigations including efficacy and tolerability analyses may be necessary for the clinical acceptance of ginseng components in combination with conventional AD drugs.

KEYWORDS:

AChE, acetylcholinesterase; AD, Alzheimer's disease; APP, amyloid precursor protein; Adjuvant; Alzheimer's disease; Aβ, amyloid β-protein; BDNF, brain-derived neurotrophic factor; EGF, Epidermal growth factor; GLP151, ginseng major latex-like protein 151; Ginsenoside; Gintonin; LPA, Lysophosphatidic acid; NGF, nerve growth factor; NMDA, n-methyl-d-aspartic acid; PI3K, phosphoinositide-3 kinase; PPARγ, peroxisome proliferator-activated receptor-γ; Panax ginseng; ROS, reactive oxygen species; sAPPα, soluble amyloid precursor protein α

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center